Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel Sells 6,667 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel sold 6,667 shares of the firm’s stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $21.93, for a total transaction of $146,207.31. Following the completion of the transaction, the chief operating officer now directly owns 329,977 shares of the company’s stock, valued at $7,236,395.61. This represents a 1.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Anish Patel also recently made the following trade(s):

• On Tuesday, January 7th, Anish Patel sold 21,700 shares of Enliven Therapeutics stock. The shares were sold at an average price of $24.18, for a total value of $524,706.00.

Enliven Therapeutics Trading Down 2.0 %

NASDAQ ELVN opened at $21.55 on Tuesday. Enliven Therapeutics, Inc. has a 1-year low of $10.90 and a 1-year high of $30.03. The firm’s fifty day simple moving average is $22.77 and its 200-day simple moving average is $24.23. The company has a market capitalization of $1.05 billion, a PE ratio of -11.34 and a beta of 1.03.

Analyst Ratings Changes

Several brokerages recently issued reports on ELVN. BTIG Research began coverage on Enliven Therapeutics in a research note on Friday, December 13th. They issued a “buy” rating and a $42.00 price objective for the company. Robert W. Baird increased their price target on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, November 15th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $38.25.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of ELVN. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Enliven Therapeutics by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company’s stock valued at $232,000 after buying an additional 3,559 shares during the last quarter. SG Americas Securities LLC acquired a new stake in Enliven Therapeutics in the third quarter valued at approximately $256,000. Verition Fund Management LLC bought a new stake in Enliven Therapeutics in the third quarter worth approximately $271,000. The Manufacturers Life Insurance Company acquired a new position in shares of Enliven Therapeutics during the 2nd quarter worth $322,000. Finally, Quest Partners LLC raised its holdings in shares of Enliven Therapeutics by 1,226.4% during the 3rd quarter. Quest Partners LLC now owns 21,117 shares of the company’s stock valued at $539,000 after purchasing an additional 19,525 shares in the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.